Research Analysts Offer Predictions for NovoCure Q1 Earnings

NovoCure Limited (NASDAQ:NVCR) – Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of NovoCure in a report released on Wednesday, April 16th. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will post earnings per share of ($0.74) for the quarter, down from their previous forecast of ($0.71). Wedbush has a “Neutral” rating and a $27.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. Wedbush also issued estimates for NovoCure’s Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.87) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.74) EPS and FY2027 earnings at ($2.64) EPS.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of NovoCure from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of NovoCure in a research report on Tuesday, January 14th. Finally, StockNews.com upgraded NovoCure from a “sell” rating to a “hold” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.17.

NovoCure Price Performance

NVCR opened at $15.58 on Friday. The stock has a 50-day moving average price of $19.06 and a 200-day moving average price of $21.53. The stock has a market capitalization of $1.71 billion, a P/E ratio of -11.13 and a beta of 0.65. NovoCure has a 12-month low of $11.70 and a 12-month high of $34.13. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.27). NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The company had revenue of $161.27 million during the quarter, compared to the consensus estimate of $161.30 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Exchange Traded Concepts LLC raised its holdings in NovoCure by 31.2% in the first quarter. Exchange Traded Concepts LLC now owns 37,812 shares of the medical equipment provider’s stock worth $674,000 after purchasing an additional 9,001 shares in the last quarter. Simon Quick Advisors LLC bought a new stake in shares of NovoCure in the 1st quarter worth approximately $255,000. SG Americas Securities LLC purchased a new position in NovoCure during the first quarter valued at $527,000. Rhumbline Advisers raised its position in shares of NovoCure by 3.8% in the 1st quarter. Rhumbline Advisers now owns 150,952 shares of the medical equipment provider’s stock worth $2,690,000 after purchasing an additional 5,483 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in NovoCure by 1,675.0% during the 1st quarter. GAMMA Investing LLC now owns 49,967 shares of the medical equipment provider’s stock valued at $890,000 after purchasing an additional 47,152 shares during the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.